Association of Tranexamic Acid Administration With Mortality and Thromboembolic Events in Patients With Traumatic Injury

Authors:

Abstract
Tranexamic acid is a widely available and low-cost medication to limit and manage hemorrhage. Tranexamic acid is indicated for menorrhagia and bleeding in patients with hemophilia1 but also commonly administered off-label for bleeding related to cardiac surgery, orthopedic surgery, and traumatic injuries.1 Many studies2 have sought to confirm or refute the hypothesis that tranexamic acid improves morbidity and mortality among the severely injured. In 2020, the results from 2 new randomized clinical trials (RCTs) on tranexamic acid in trauma3,4 were published. The present work was performed to provide an updated, high-quality systematic review and meta-analysis on the use of tranexamic acid in patients with trauma.

This publication has 52 references indexed in Scilit: